Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

73.22 +12.83 (+21.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,369,416
Open 65.75
Bid (Size) 74.50 (1)
Ask (Size) 74.74 (1)
Prev. Close 60.39
Today's Range 63.67 - 75.67
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug. 
Via The Motley Fool
3 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
+300.55%
+300.55%
1 Month
+18.23%
+18.23%
3 Month
+13.20%
+13.20%
6 Month
+6.33%
+6.33%
1 Year
+586.22%
+586.22%

More News

Read More
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Via Investor's Business Daily
Exposures Product Safety
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
Via The Motley Fool
An Overview of Viking Therapeutics's Earnings
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Viking Therapeutics Unusual Options Activity
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Where Will Viking Therapeutics Be in 5 Years?
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $100 Right Now
Via The Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Why Viking Therapeutics Stock Topped the Market Today
Via The Motley Fool
Is Viking Therapeutics Stock a Buy?
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.